Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage.
It is a $9.38B healthcare company. Revenue grew 29.4% over the last year, it keeps 12¢ of every dollar of sales as profit, and its net debt equals ~0.7 years of free cash flow. It trades at 25.0× earnings — near the lowest of its own history.
- Website
- insulet.com
- Location
- Acton, MA
- Employees
- 5 400
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth, health and quality; Moat lags behind.
Valuation69
- P/E vs own history1th pct · 25/25
- FCF yield3.1% · 12/25
- P/S3.1x · 20/25
- EV/EBITDA21.8x · 12/25
Growth100
- Revenue CAGR25.3% · 25/25
- Net income CAGR95.8% · 25/25
- EPS CAGR ~5Y101.6% · 25/25
- Fwd implied growth30.6% · 25/25
Profitability72
- ROIC14.3% · 12/25
- ROE17.4% · 20/25
- Net margin12.3% · 20/25
- Operating margin16.9% · 20/25
Health95
- Altman Z4.61 · 25/25
- Current ratio2.81 · 25/25
- Interest coverage33.6x · 25/25
- Net cash / debtD/A 7% · 20/25
Quality82
- Piotroski F7/9 · 22/25
- Beneish M-2.83 · 25/25
- FCF conversion78% · 15/25
- Margin stabilityσ 6.9% · 20/25
Moat31
- ROIC >12% years3/10 yrs · 6/25
- Median gross margin65.4% · 25/25
- FCF-positive years3/10 yrs · 0/25
- Worst-year net marginworst -7.9% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- Q2 2026Insiders2 open-market insider purchases~6K shares bought by insiders
- FY2024FinancialBest year on record$418M net income
- FY2021FinancialRevenue crossed $1B$1.10B for the year
- FY2018FinancialTurned profitable$3.29M net income after a loss year
- 1978ProductBetween 1978 and 1988, Robert Channon, working with Guy's Hospital and the Bristol Royal Infirmary, developed a…
- 1976ProductThe first commercialized insulin pump was created and was named the Biostator
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (71.1%)
- Revenue growing 29.4% year over year
- Could repay net debt from ~1.4 years of free cash flow
- Interest covered 33.6× by operating earnings
- Piotroski F-Score 7/9 — fundamentally strong checklist
Watch-outs
- Loss-making in 2 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+29.4% YoY
- Profitable — makes more than it spends$375M TTM
- Profit growing — earnings are higher than last year+273.8% YoY
- Generates cash — cash left after running and investing$294M TTM
- Debt under control — could handle its obligations~0.7y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$9.38B market cap
- Not printing shares — share count not ballooning — you keep your slice+9.0% shares over ~5y
- Proven track record — years of profitability behind it8/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 4.6 — safe
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 25.0
Peer comparisonInsulet Corporation vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| PODD this company | $9.4B | 25.0 | +29.4% | 12.3% | Strong |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: PODD vs LLY · PODD vs JNJ · PODD vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/PODD
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of PODD on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $135.28 · market cap $9.38B.